Cryopyrin-associated Periodic Syndromes

• EMA approval · 2025-10-13
  EMA Authorised: Ilaris (Canakinumab) — Novartis Europharm Limited

  The EMA authorised Ilaris (canakinumab) for use in Cryopyrin-Associated Periodic Syndromes, juvenile idiopathic arthritis, and gout.

• FDA approval · 2016-09-23
  FDA Approved: ILARIS — Supplemental Application (Novartis Pharmaceuticals Corporation)

  The FDA approved a supplemental application for ILARIS (canakinumab) submitted by Novartis Pharmaceuticals Corporation, resulting in an upda…

• FDA approval · 2010-09-30
  FDA Approved: ARCALYST — Supplemental Application (Kiniksa Pharmaceuticals (UK), Ltd.)

  The FDA approved a supplemental application for ARCALYST (rilonacept) by Kiniksa Pharmaceuticals (UK), Ltd., updating the existing approval.

• FDA approval · 2009-06-17
  FDA Approved: ILARIS — Original Application (Novartis Pharmaceuticals Corporation)

  The FDA approved ILARIS (canakinumab) under the original application for treatment of cryopyrin-associated periodic syndromes, including fam…

• FDA approval · 2008-02-27
  FDA Approved: ARCALYST — Original Application (Kiniksa Pharmaceuticals (UK), Ltd.)

  FDA approved ARCALYST (rilonacept) from its original Biologics License Application for the treatment of cryopyrin-associated periodic syndro…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.